Dasatinib hydrochloride，又称达沙替尼盐酸盐，是可口服的、ATP竞争性的Src/Abl双抑制剂。Dasatinib可诱导细胞自噬和细胞凋亡并具有抗肿瘤的活性。Dasatinib对血液和实体瘤细胞表现出非常强的抗增殖活性，并在CML移植瘤动物模型中表现出完全的肿瘤消退和低毒性特性。在表达野生型Bcr-Abl的细胞系中，Dasatinib比伊马替尼(imatinib)的活性高325倍(IC₅₀: 0.6 versus 280 nM)。

参考文献

[1] O'Hare T, Walters DK, Stoffregen EP, et al. In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res. 2005 Jun 1;65(11):4500-5. doi: 10.1158/0008-5472(IF:8.378).

[2] Lombardo LJ, Lee FY, Chen P, et al. Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J Med Chem. 2004 Dec 30;47(27):6658-61. doi: 10.1021/jm049486a(IF:6.054).

-25~-15℃保存，有效期3年。